Specifically, alkyne-modified Sorafenib (11), a kinase inhibitor with multiple targets such as Vascular Endothelial Growth Factor Receptor (VEGFR-2) and Receptor Tyrosine Kinase (EphB4), and the azido-modified VHL and CRBN ligand (compounds 12 and 13, respectively) were developed and successfully used for the synthesis of tumor-selective PROTACs assembled in situ via the CuAAC reaction (compounds 14 and 15, respectively) [46,47]. This evidence concerns the gene KDR and neoplasm.